WHO ICTRP trial
Evaluate the Efficacy of Siddha Treatment in Patients with Novel Coronavirus…
CTRI/2020/08/026999 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2020/08/026999 |
|---|---|
| Public title | Evaluate the Efficacy of Siddha Treatment in Patients with Novel Coronavirus Infectious Disease (COVID-19) |
| Scientific title | A Prospective Randomized, Open-Label Study to Evaluate the Efficacy of Siddha Treatment in Patients with Novel Coronavirus Infectious Disease (COVID-19) in Coimbatore, Tamil Nadu - SIFRA-CBE |
| Primary sponsor | Indian Medicine and Homeopathy Department Chennai |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere |
| Interventions | Intervention1: Standard Drug Regimen followed by Tamil Nadu Government: 1.Tab.Ivermectin 12 mg STAT 2.Tab.Doxycycline 100 mg 1-0-1 for 5 days 3.Tab.Vitamin C- 500 mg 1 OD 4.Tab.Zinc 1 OD 5.Tab.paracetamol - 500 mg SOS 6. Cap.Omeprazole 20… |
| Registration date | May 8, 2020 |
| Target size | 100 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: